Key facts
- Gregor Diagnostics’s last known valuation is $9.5M (Oct 2021).
- It has raised $14.6M across 4 recorded rounds; the latest was Seed Round ($4.4M) in Mar 2023.
- Notable investors include First Round Capital, gBETA, Zachary Weinberg, Wisconsin Economic Development, WARF Ventures — 9 tracked in total.
- Gregor Diagnostics has filed 4 Form Ds with the SEC since 2018, most recently Oct 2023 ($4.4M sold to 4 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 4 rounds
- ·The complete investor list — 9 names
- ·Watchlist + deal alerts for Gregor Diagnostics
Funding rounds
4 roundsAbout Gregor Diagnostics
Operator of a molecular diagnostics company intended to develop a novel screening test for prostate cancer. The company's cancer test is created using seminal fluid as a sample source, can detect prostate cancer at the earliest stages of the disease and differentiate between indolent and aggressive cancer, enabling physicians to reduce overdiagnosis and overtreatment of indolent prostate cancer and more effectively detect and management of aggressive prostate cancer.
- Sector
- Healthcare
- HQ
- Madison, WI, United States
- Founded
- 2016
- Employees
- 8
- Website
- gregordiagnostics.com/
- Ownership
- Privately Held (backing)
Gregor Diagnostics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Gregor Diagnostics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Gregor Diagnostics in its N-PORT filings yet. We sweep new filings monthly.